While GSK’s ego may have been bruised after an initial failure to develop a COVID-19 shot, its bread-and-butter immunization business is making strides elsewhere. Look no further than malaria, where ...

LONDON, Sept 7 (Reuters) - Encouraging new data on a malaria vaccine from Oxford University bodes well for global effort to combat the mosquito-borne disease that kills a child every minute, its ...

Please provide your email address to receive an email when new articles are posted on . The Committee for Medicinal Products for Human Use of the European Medicines Agency recently adopted a positive ...

Follow this author to personalize your feed and get instant alerts. WHY FOLLOW? Custom Feed: See the stories that matter most to you. Smart Alerts: Get notified about major news as it happens. Update ...

LONDON — Starting Monday, a new, highly effective malaria vaccine will be rolled out for the first time, as an immunization campaign for children kicks off in Cameroon — a day that global health ...

The active ingredient of Mosquirix consists of amino acids found in the circumsporozoite protein that is secreted during the sporozoite stage of the parasite's life cycle, after it enters the ...

Share on Pinterest An effective new malaria vaccine, Mosquirix, has rolled out in Cameroon and could reduce the risk of all-cause mortality in children by 13%. Image credit: ETIENNE NSOM/Getty Images.

Malaria parasites can shuffle genes, creating different strains in different people and eluding the immune system in the process. The phenomenon, unearthed in a new study, could put the efficacy of ...

Mosquirix, the world's first malaria vaccine, has been approved by the European Medicine Agency. This drug is designed for use in young children, in an effort to reduce the incidence of this often ...

European Union (EU) regulators today approved the world's first malaria vaccine for use outside the EU among children aged 6 weeks to 17 months. The new vaccine (Mosquirix, GlaxoSmithKline Biologicals ...

LONDON - The world's first malaria vaccine, developed by GlaxoSmithKline, provides some protection after three doses but its effect dwindles to almost nothing after seven years, scientists said on ...